Everything below concerns prohibited substance. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-11-16. Numbers and descriptions here follow the published literature rather than marketing material.
Dry peptide powder is commonly kept at −20 °C in a desiccated container away from light, a practice that limits moisture uptake and oxidation. Once dissolved, solutions are generally held at 2–8 °C for short periods or frozen at −20 °C or lower for longer storage, with repeated freeze-thaw cycles avoided. Hydrolysis and oxidation are the main degradation routes for peptides in solution, and both accelerate at higher temperature or extreme pH. Published stability data specific to TB-500 are limited, so shelf life should be treated as uncertain.
Identity and purity checks for peptide material typically combine reversed-phase high-performance liquid chromatography with mass measurement, since retention time alone cannot confirm a sequence. Mass measurement verifies the expected molecular mass within instrument tolerance, while chromatographic peak area provides a purity estimate. Anti-doping analysis of urine uses related but more sensitive workflows, sometimes after solid-phase extraction. For research material, batch documentation, certificate content, and independent testing are common points of scrutiny, because supply chains outside pharmaceutical regulation vary widely in the paperwork they provide.
Lyophilized TB-500 is hygroscopic and should be kept dry before use. The usual storage recommendation for the solid is -20 °C, protected from light and moisture. Once dissolved, the peptide is less stable, and repeated freeze-thaw cycles can promote aggregation or degradation. Laboratories often divide a reconstituted solution into single-use aliquots and store them at -80 °C. Exact stability limits depend on buffer, pH, and concentration, so published data do not define a single universal condition.
Identity and purity are checked with chromatographic and mass spectrometric methods. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities, while mass spectrometry confirms the expected molecular mass. A certificate of analysis may report a purity percentage, but the laboratory should still verify the material independently. Common quality concerns include truncated sequences, deamidation, oxidation, and residual solvents from synthesis. Because TB-500 is short, some impurities can differ from the target by only a few mass units.
| Property | Value | Notes |
|---|---|---|
| Reconstitution solvent | Sterile water or aqueous buffer | Aseptic technique recommended |
| Post-reconstitution storage | 2–8 °C short term; frozen for longer periods | Avoid repeated freeze-thaw cycles |
| Typical purity assay | Reversed-phase HPLC | Peak area used to estimate purity |
| Identity confirmation | Mass measurement | Compares observed value with expected mass |
| Main degradation routes | Hydrolysis and oxidation | Accelerated by heat and extreme pH |
Animal work has examined the peptide in models of cardiac injury, skin wounding, and corneal repair, with reported outcomes covering cell migration, inflammatory cell influx, and tissue remodeling. Several of those experiments used the full-length protein or longer fragments instead of the seven-residue sequence, which makes direct comparison between reports difficult. Results are generally described as tissue-dependent, and effect sizes vary considerably across laboratories. Independent replication is uneven, so the overall picture is incomplete rather than settled.
Controlled human trials of the short fragment are scarce. Much of what appears in review articles is extrapolated from animal models or from studies of the parent protein, and literature searches return a larger body of cardiac and ophthalmic work on thymosin beta-4 than on the abbreviated peptide. Regulatory treatment differs by jurisdiction, and in several countries the material is handled as a research chemical rather than an approved therapeutic. Statements about human benefit should be read as provisional.
Biological interest in this peptide centers on its relationship to actin dynamics. Thymosin beta-4 binds monomeric actin through an LKKTET motif, and a short sequence carrying that motif can compete with other actin-binding proteins in cell-free preparations. Investigators propose that such competition shifts the balance between filament assembly and disassembly, which in turn affects how readily a cell extends protrusions and migrates. Most of the supporting observations come from cultured cells and purified protein systems rather than from intact organisms.
Detection in biological matrices generally relies on liquid chromatography coupled with tandem mass spectrometry, because the peptide lacks a convenient ultraviolet chromophore beyond the amide backbone. Immunoassays have been described, but antibodies raised against the fragment can cross-react with the full-length protein or with unrelated peptides, so findings usually require confirmation by a second technique. Sample preparation typically involves protein precipitation followed by solid-phase extraction. Reported detection windows depend on dose, route, matrix, and instrument sensitivity.
Lyophilised material is stable for extended periods when kept dry and cold, and suppliers typically recommend storage well below freezing. Once dissolved, the peptide is handled at refrigeration temperatures and used within a short period, because peptide bonds and the acetylated terminus can be affected by repeated freeze-thaw cycles, proteases, or extreme pH. Bacteriostatic water and saline are both described as solvents, although preservatives can interfere with some analytical workflows. Reconstituted solutions are inspected for particulates before use.
Sports authorities classify the peptide as a prohibited substance, and it appears on the World Anti-Doping Agency list under peptide hormones, growth factors, and related substances. Racing jurisdictions for horses and dogs have issued separate restrictions, and several national bodies treat it as a controlled or prescription-only item. As a research chemical it is sold without a therapeutic indication, and labels usually state that the product is not for human or veterinary use. Regulatory treatment therefore varies by country.
TB-500 is a catalogue name applied to a synthetic peptide related to thymosin beta-4, an actin-binding protein found in most mammalian cells. Suppliers do not use the label consistently: some describe it as the full 43-residue protein, others as a short fragment from the actin-binding region, and others as a related tetrapeptide. Because the name is commercial rather than chemical, two products sold under it may not contain the same molecule. This naming ambiguity is the first point to check in any description of the material.
The most frequently cited identity is a seven-residue fragment with the sequence LKKTETQ, taken from the actin-binding domain of the parent protein. A separate molecule, N-acetyl-seryl-aspartyl-lysyl-proline, often shortened to Ac-SDKP, derives from the same protein's N-terminal region and appears in overlapping literature. Reported molecular masses therefore differ between sources, and a mass value on its own does not establish which fragment is present. Confirmation requires a defined sequence rather than a single number.
Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.
== Richest royals == The Crown Property Bureau presides over the wealth of Thailand's king and royal family, judged to be the world's richest. Its holdings include over 7,588 rai (1,214.1 ha; 3,000 acres) of land in central Bangkok and shares in Siam Cement and Siam Commercial Bank. The king also owns the 545-carat Golden Jubilee Diamond, the largest cut and faceted diamond in the world.
== Further reading == Peter Harper; Lois Reynolds; Tilli Tansey, eds. (2010). Clinical Genetics in Britain: Origins and development. Wellcome Witnesses to Contemporary Medicine. History of Modern Biomedicine Research Group. ISBN 978-0-85484-127-1. Wikidata Q29581774.
=== Post-RDS-1 === In the subsequent years it became increasingly valuable to gather information on the Soviet nuclear weapons program, which resulted in the development of technologies that could gather airborne particles in a WB-29 weather reconnaissance plane. On September 3, 1949, these particles were used to determine that the detonation time of the first Soviet atomic test, "Joe 1". Further analysis revealed that this bomb was a replicate of the "Fat Man", which was the bomb dropped on Nagasaki in 1945. This investigative methodology combined radiochemistry and other techniques to gather intelligence on nuclear activities. During the 1961 Soviet nuclear tests, most of the Novaya Zemlya shots were likely monitored by RB-47 aircraft flown from RAF Brize Norton and elsewhere. In August, Khrushchev had announced the existence 100 megaton Soviet bomb, ultimately tested as the Tsar Bomba. A JKC-135A was rapidly outfitted to monitor the test, under Operation Speed Light Bravo. Photomutiplier detectors in UV, visibile, and near-IR were used, with multiplication factors above 100 million. Cine and stills cameras were used, with lens resolutions up to 70 mm. One side of the aircraft was scorched. It has been argued that if the Tsar Bomba had been configured to yield 100 megatons instead of the decided 50, that the aircraft would have been destroyed. The United Kingdom worked with the US to monitor Soviet tests. RAF debris collection missions flew from the summer of 1949 from Scotland, Northern Ireland, and Gibraltar, filling the North Atlantic.
Sources: en.wikipedia.org
Maggot therapy is the intentional introduction of live, disinfected blow fly larvae (maggots) into soft tissue wounds to selectively clean out the necrotic tissue. This helps to prevent infection; it also speeds healing of chronically infected wounds and ulcers. Military surgeons since classical antiquity noticed that wounds which had been left untreated for several days, and which had become infested with maggots, healed better than wounds not so infested. Maggots secrete several chemicals that kill microbes, including allantoin, urea, phenylacetic acid, phenylacetaldehyde, calcium carbonate, proteolytic enzymes, and many others. Maggots were used for wound healing by the Maya and by indigenous Australians. More recently, they were used in Renaissance Europe, in the Napoleonic Wars, the American Civil War, and in the First and Second World Wars. It continues to be used in military medicine.
==== Colombia ==== According to a 2010 USDA Foreign Agricultural Service report, each small town in Colombia typically has a fresh food market that is supplied by local production and opens at least once a week. The report described both retail and wholesale markets that provide food products for "Mom'n Pop stores". It estimated the number of such markets at around 2,000, but noted that the number was slowly decreasing in large cities despite the presence of large markets like Corabastos in Bogotá.
== See also == List of pre-Columbian cultures Domesticated plants of Mesoamerica Agriculture in Mesoamerica Mesoamerican cuisine Mesoamerican diet and subsistence Mesoamerican architecture Indigenous music of North America Painting in the Americas before European colonization Mesoamerican chronology History portal North America portal Central America portal South America portal
=== Limitations === As a standalone technique, RNP-MaP cannot be used to determine protein-RNA binding mechanisms or protein identities. In order to do so, RNP-MaP must be used in conjunction with other techniques such as CLIP and mass spectrometry. RNP-MaP requires extremely high read-depths for analysis. To identify RNP-MaP sites, 1000x sequencing coverage is required, while RNP-MaP correlation sites require 10,000x sequencing coverage. There are severe limitations on the ability to characterize RNP-MaP correlations between distant (>500 nucleotides) RNP-MaP sites. This is due to limitations of MaP reverse transcription processivity (500-600 nucleotides) and sequencing instrument clustering (<1,000 nucleotides).
Sources: en.wikipedia.org
Standard practice is a desiccated container at −20 °C, protected from light and kept sealed between uses. Letting the vial reach room temperature before opening reduces condensation on the powder. Repeated warming and cooling of the whole container is generally avoided.
There is no broadly accepted figure for TB-500. Laboratory practice is short-term storage at 2–8 °C with longer-term aliquots frozen, and degradation is expected to increase with time and temperature. Users typically rely on their own stability checks rather than published data.
Mass measurement provides the clearest confirmation by matching an observed value to the expected one. Reversed-phase chromatography adds a purity estimate through peak integration. Combining both is standard because neither alone establishes identity and purity together.
The dry powder is normally kept at -20 °C, protected from light and moisture. Reconstituted solutions are often divided into aliquots and stored at -80 °C to reduce freeze-thaw damage.